Clinical Trial: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07293260) titled 'Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial' on Dec. 17.

Brief Summary: The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).

Study Start Date: March 21, 2026

Study Type: INTERVENTIONAL

Condition: Cardiovascular Disease

Intervention: DRUG: Olpasiran

Olpasiran will be administered SC.

DRUG: Placebo

Placebo will be administered SC.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Amgen

Published by HT Digita...